Jul 28, 2015
RAND researchers conducted a systematic review that synthesized evidence from randomized controlled trials of Mindfulness-Based Relapse Prevention (MBRP) — used as an adjunctive therapy or monotherapy — to provide estimates of its efficacy and safety for treating adults diagnosed with alcohol, opioid, stimulant, or cannabis use disorder.
Outcomes of interest included relapse, frequency and quantity of substance use, withdrawal/craving symptoms, treatment dropout, functional status, health-related quality of life, recovery outcomes, and adverse events. When possible, meta-analyses and meta-regressions were conducted using the Hartung-Knapp-Sidik-Jonkman method for random-effects models. Quality of evidence was assessed using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach.
Six trials (reported in 20 publications) with 685 participants were included. Evidence was insufficient to determine whether MBRP effects differ by type of substance use targeted. There were no significant effects for MBRP as an adjunctive therapy or a stand-alone monotherapy for most outcomes. There were statistically significant effects for MBRP as an adjunctive therapy for health-related quality of life and legal problems, yet this was based on very low quality of evidence from one randomized controlled trial. Effects did not appear to systematically differ by identified comparison group. The available evidence on adverse events is very limited.
There were no statistically significant differences between MBRP and any comparators for substance use outcomes. Given the quality of evidence, there is uncertainty in the magnitude or stability of effect estimates. To provide more firm conclusions about the efficacy and safety of MBRP, future RCTs on this intervention are needed.
Excluded Full-Text Articles